Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

Beam Therapeutics

General information

Main focus: Base editing for the treatment of genetic diseases and cancer

Company stage: Pre-clinical

Diseases: Sickle cell disease, beta-thalassemia, acute lymphoblastic leukaemia (ALL), alpha-1 antitrypsin deficiency, glycogen storage disorder-1, Stargardt disease

Genome-editing tool: Cytosine base editor, adesonine base editor, prime editing

Funding stage: Public (NASDAQ:BEAM)

Location: Cambridge, MA, USA



Partners: Prime Medicine, Verve Therapeutics, Sana Biotechnology, Apellis Pharmaceuticals, Bio Palette

Beam Therapeutics is developing precision genetic medicines through base editing. Founded by leading scientists from the CRISPR field, Beam is pursuing therapies for serious diseases using its proprietary base-editing technology, which can make precise edits to single base pairs in DNA and RNA. The company's most advanced programme is in IND-enabling studies for sickle cell anaemia.


HashtagBeam Therapeutics Inc.

Company: Beam Therapeutics
Search CRISPR Medicine